Patent ID: 11931414
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. The Ligand Drug Conjugate compound of claim 1, wherein L-(LR- of Formula 1 has the structure of:, or a salt thereof, wherein
the indicated (#) atom is from the Ligand Unit which is an antibody or an antigen-binding fragment thereof; and wherein the wavy line indicates the site of covalent attachment to the remainder of the Ligand Drug Conjugate compound structure, or
wherein L-(LR- of Formula 1 has the structure of:, or a salt thereof, wherein
the indicated (#) sulfur atom is from the Ligand Unit which is an antibody or an antigen-binding fragment thereof,
R6 is hydrogen or an optionally substituted C1-C6 alkyl;
AO is a second optional Stretcher Unit; and
the wavy line indicates the site of covalent attachment to the remainder of the Conjugate structure, or
wherein L-(LR- of Formula 1 has the structure of:, wherein the indicated (#) sulfur atom is from the Ligand Unit which is an antibody or an antigen-binding fragment thereof and the wavy line indicates the site of covalent attachment to the remainder of the Ligand Drug Conjugate compound structure, or
wherein L-(LR- of Formula 1 has the structure of:, or a salt thereof, wherein
the indicated (#) sulfur atom is from the Ligand Unit which is an antibody or an antigen-binding fragment thereof, and
R6 is hydrogen or an optionally substituted C1-C6 alkyl;
AO is a second optional Stretcher Unit;
BU is a Basic Unit;
Ra2 is —H or optionally substituted C1-C12 alkyl;
the dotted curved line indicates optional cyclization so that in the absence of said cyclization BU is an acyclic Basic Unit or in the presence of said cyclization BU is a cyclized Basic Unit in which Ra2 as C1-C6 alkyl and BU together with the carbon atom to which both are attached and a carbon atom of Ra2, define an optionally substituted C3-C20 heterocyclo containing a skeletal basic nitrogen atom of a secondary or tertiary amine functional group of BU,
wherein the basic nitrogen atom of the acyclic Basic Unit or cyclic Basic Unit is optionally suitably protected by a nitrogen protecting group, dependent on the degree of substitution of the basic nitrogen atom, or is optionally protonated; and
the wavy line indicates the site of covalent attachment to the remainder of the Ligand Drug Conjugate compound structure, or
wherein L-(LR- of Formula 1 or a compound thereof has the structure of:, or a salt thereof, wherein the basic nitrogen atom is optionally suitably protected by a nitrogen protecting group, or is optionally protonated; and
the indicated (#) sulfur atom is from the Ligand Unit which is an antibody or an antigen-binding fragment thereof; and the wavy line indicates the site of covalent attachment to the remainder of the Ligand Drug Conjugate compound structure, or
wherein L-(LR- of Formula 1 or compound thereof has the structure of:, or a salt thereof, wherein
the basic nitrogen atom is optionally suitably protected by a nitrogen protecting group, or is optionally protonated; and
the indicated (#) sulfur atom is from the Ligand Unit which is an antibody or an antigen-binding fragment thereof; and the wavy line indicates the site of covalent attachment to the remainder of the Conjugate structure.